|
Results
20-Jan-24
|
|
|
|
|
Analysis
|
|
Atul
|
NP down 33%
|
|
|
Consolidated
net sales (including other operating income) of Atul has declined 10.29% to Rs
1137.8 crore in Q3FY24 compared to Q3FY23.
Sales of Life Science Chemicals segment has gone down 31.30% to Rs
337.82 crore (accounting for 28.40% of total sales). Sales of Performance & Other Chemicals
segment has gone up 1.52% to Rs 840.63 crore (accounting for 70.68% of total
sales). Sales of Others segment fell
31.49% to Rs 10.92 crore (accounting for 0.92% of total sales). Inter-segment sales came down from Rs 67.43
crore to Rs 51.57 crore.
Profit
before interest, tax and other unallocable items (PBIT) has slumped 19.88% to
Rs 107.81 crore. PBIT of Life Science
Chemicals segment fell 61.71% to Rs 42.40 crore (accounting for 39.33% of total
PBIT). PBIT of Performance & Other
Chemicals segment rose 208.84% to Rs 65.69 crore (accounting for 60.93% of
total PBIT). PBIT of Others reported
loss of Rs 0.28 crore compared to profit of Rs 2.55 crore.
PBIT
margin of Life Science Chemicals segment fell from 22.52% to 12.55%. PBIT margin of Performance & Other
Chemicals segment rose from 2.57% to 7.81%.
PBIT margin of Others segment fell from 16.00% to 2.56%. Overall PBIT margin fell from 10.07% to
9.06%.
Operating
profit margin has declined from 13.58% to 13.33%, leading to 11.94% decline in
operating profit to Rs 151.68 crore. Raw
material cost as a % of total sales (net of stock adjustments) increased from
48.72% to 49.65%. Purchase of finished
goods cost rose from 3.18% to 3.49%.
Employee cost increased from 7.16% to 8.87%. Other expenses fell from 27.11% to
24.74%. Power and Oil fuel cost fell
from 13.23% to 11.38%.
Other
income fell 34.38% to Rs 15 crore. PBIDT
fell 14.57% to Rs 166.68 crore.
Provision for interest fell 3.64% to Rs 2.12 crore.
PBDT
fell 14.70% to Rs 164.56 crore.
Provision for depreciation rose 21.50% to Rs 61.21 crore.
Profit
before tax down 27.49% to Rs 103.35 crore.
Provision for tax was expense of Rs 33.4 crore, compared to Rs 39.4
crore. Effective tax rate was 31.67%
compared to 27.69%.
Net
profit attributable to owners of the company decreased 32.50% to Rs 70.94
crore.
Promoters’
stake was 45.07% as of 31 December 2023 ,compared to 45.06% as of 31 December
2022 . Promoters pledged stake was 0.98%
as of 31 December 2023 ,compared to 0.75% as of 31 December 2022.
For year-to-date (YTD)
results analysis
Net
sales (including other operating income) of Atul has declined 16.98% to Rs
3513.53 crore. Sales of Life Science
Chemicals segment has gone down 32.28% to Rs 1,050.02 crore (accounting for
28.59% of total sales). Sales of
Performance & Other Chemicals segment has gone down 10.18% to Rs 2,583.51
crore (accounting for 70.34% of total sales).
Sales of Others segment rose 6.91% to Rs 39.17 crore (accounting for
1.07% of total sales). Inter-segment
sales came down from Rs 231.14 crore to Rs 159.17 crore.
Profit
before interest, tax and other unallocable items (PBIT) has slumped 33.71% to
Rs 368.99 crore. PBIT of Life Science
Chemicals segment fell 58.93% to Rs 136.38 crore (accounting for 36.96% of
total PBIT). PBIT of Performance &
Other Chemicals segment rose 1.07% to Rs 226.93 crore (accounting for 61.50% of
total PBIT). PBIT of Others segment rose
6,211.11% to Rs 5.68 crore (accounting for 1.54% of total PBIT).
PBIT
margin of Life Science Chemicals segment fell from 21.41% to 12.99%. PBIT margin of Performance & Other
Chemicals segment rose from 7.81% to 8.78%.
PBIT margin of Others segment rose from 0.25% to 14.50%. Overall PBIT margin fell from 12.47% to
10.05%.
Operating
profit margin has declined from 14.78% to 13.92%, leading to 21.80% decline in
operating profit to Rs 489.13 crore. Raw
material cost as a % of total sales (net of stock adjustments) decreased from
48.76% to 47.61%. Purchase of finished
goods cost rose from 4.04% to 4.16%.
Employee cost increased from 6.45% to 8.84%. Other expenses fell from 26.10% to
24.76%. Power and Oil fuel cost rose
from 11.82% to 11.86%.
Other
income fell 50% to Rs 45.33 crore. PBIDT
fell 25.37% to Rs 534.46 crore. Provision
for interest rose 5.25% to Rs 6.01 crore.
PBDT
fell 25.62% to Rs 528.45 crore.
Provision for depreciation rose 13.90% to Rs 167.13 crore.
Profit
before tax down 35.90% to Rs 361.32 crore.
Share of profit/loss was 184.62% higher at Rs 6.29 crore. Provision for tax was expense of Rs 102.28
crore, compared to Rs 151.48 crore.
Effective tax rate was 27.82% compared to 26.77%.
Net
profit attributable to owners of the company decreased 37.08% to Rs 264.61
crore.
Promoters’
stake was 45.07% as of 31 December 2023 ,compared to 45.06% as of 31 December
2022 . Promoters pledged stake was 0.98%
as of 31 December 2023 ,compared to 0.75% as of 31 December 2022.
The
scrip is currently trading at Rs 6501
Atul : Consolidated Results
|
Particulars
|
2312 (03)
|
2212 (03)
|
Var.(%)
|
2312 (09)
|
2212 (09)
|
Var.(%)
|
2303 (12)
|
2203 (12)
|
Var.(%)
|
Net Sales (including other operating income)
|
1,137.80
|
1,268.25
|
-10
|
3,513.53
|
4,232.37
|
-17
|
5,427.52
|
5,080.89
|
7
|
OPM (%)
|
13.3
|
13.6
|
|
13.9
|
14.8
|
|
14.3
|
17.9
|
|
OP
|
151.68
|
172.25
|
-12
|
489.13
|
625.48
|
-22
|
774.85
|
911.44
|
-15
|
Other Inc.
|
15.00
|
22.86
|
-34
|
45.33
|
90.66
|
-50
|
114.87
|
76
|
51
|
PBIDT
|
166.68
|
195.11
|
-15
|
534.46
|
716.14
|
-25
|
889.72
|
987.44
|
-10
|
Interest
|
2.12
|
2.20
|
-4
|
6.01
|
5.71
|
5
|
7.9
|
9.17
|
-14
|
PBDT
|
164.56
|
192.91
|
-15
|
528.45
|
710.43
|
-26
|
881.82
|
978.27
|
-10
|
Depreciation
|
61.21
|
50.38
|
22
|
167.13
|
146.74
|
14
|
197.81
|
176.69
|
12
|
PBT
|
103.35
|
142.53
|
-27
|
361.32
|
563.69
|
-36
|
684.01
|
801.58
|
-15
|
Share of Profit/(Loss) from Associates
|
2.10
|
-0.25
|
LP
|
6.29
|
2.21
|
185
|
3.83
|
8.16
|
-53
|
PBT before EO
|
105.45
|
142.28
|
-26
|
367.61
|
565.9
|
-35
|
687.84
|
809.74
|
-15
|
EO Income
|
0.00
|
0.00
|
-
|
0
|
0
|
-
|
0
|
0
|
-
|
PBT after EO
|
105.45
|
142.28
|
-26
|
367.61
|
565.9
|
-35
|
687.84
|
809.74
|
-15
|
Taxation
|
33.40
|
39.40
|
-15
|
102.28
|
151.48
|
-32
|
181.21
|
205
|
-12
|
PAT
|
72.05
|
102.88
|
-30
|
265.33
|
414.42
|
-36
|
506.63
|
604.74
|
-16
|
Minority Interest (MI)
|
1.11
|
-2.22
|
PL
|
0.72
|
-6.11
|
PL
|
-7.46
|
0.48
|
LP
|
Net profit
|
70.94
|
105.10
|
-33
|
264.61
|
420.53
|
-37
|
514.09
|
604.26
|
-15
|
EPS (Rs)*
|
#
|
#
|
|
#
|
#
|
|
174.2
|
204.7
|
|
Notes
|
* EPS is on current equity of Rs 29.51 crore, Face value of Rs
10, Excluding extraordinary items.
|
# EPS is not annualised
|
bps : Basis points
|
EO : Extraordinary items
|
Figures in Rs crore
|
Source: Capitaline Corporate Database
|
Atul : Consolidated Segment
Results
|
|
% of (Total)
|
2312 (03)
|
2212 (03)
|
Var.(%)
|
% of (Total)
|
2312 (09)
|
2212 (09)
|
Var.(%)
|
% of (Total)
|
2303 (12)
|
2203 (12)
|
Var.(%)
|
Sales
|
|
|
|
|
Life Science Chemicals
|
28
|
337.82
|
491.73
|
-31
|
29
|
1,050.02
|
1,550.60
|
-32
|
34
|
1,959.16
|
1,465.10
|
34
|
Performance & Other Chemicals
|
71
|
840.63
|
828.01
|
2
|
70
|
2,583.51
|
2,876.27
|
-10
|
65
|
3,706.17
|
3,759.18
|
-1
|
Others
|
1
|
10.92
|
15.94
|
-31
|
1
|
39.17
|
36.64
|
7
|
1
|
49.64
|
69.98
|
-29
|
Total Reported Sales
|
100
|
1,189.37
|
1,335.68
|
-11
|
100
|
3,672.70
|
4,463.51
|
-18
|
100
|
5,714.97
|
5,294.26
|
8
|
Less: Inter segment revenues
|
|
51.57
|
67.43
|
-24
|
|
159.17
|
231.14
|
-31
|
|
287.45
|
213.37
|
35
|
Net Sales
|
|
1,137.80
|
1,268.25
|
-10
|
|
3,513.53
|
4,232.37
|
-17
|
|
5,427.52
|
5,080.89
|
7
|
PBIT
|
|
|
|
|
Life Science Chemicals
|
39
|
42.4
|
110.74
|
-62
|
37
|
136.38
|
332.04
|
-59
|
64
|
422.65
|
178.88
|
136
|
Performance & Other Chemicals
|
61
|
65.69
|
21.27
|
209
|
62
|
226.93
|
224.52
|
1
|
36
|
240.25
|
575.89
|
-58
|
Others
|
0
|
-0.28
|
2.55
|
PL
|
2
|
5.68
|
0.09
|
999
|
0
|
1.15
|
24.43
|
-95
|
Total PBIT
|
100
|
107.81
|
134.56
|
-20
|
100
|
368.99
|
556.65
|
-34
|
100
|
664.05
|
779.2
|
-15
|
Less : Interest
|
|
2.12
|
2.2
|
-4
|
|
6.01
|
5.71
|
5
|
|
7.9
|
9.17
|
-14
|
Add: Other un-allcoable
|
|
-0.24
|
9.92
|
PL
|
|
4.63
|
14.96
|
-69
|
|
31.69
|
39.71
|
-20
|
PBT
|
|
105.45
|
142.28
|
-26
|
|
367.61
|
565.9
|
-35
|
|
687.84
|
809.74
|
-15
|
|
|
Previous News |
Atul
(
Results
-
Analysis
20-Jan-24
10:57
)
|
|
Atul to hold board meeting
(
Corporate News
-
04-Nov-23
10:37
)
|
|
Atul
(
Results
-
Analysis
22-Jul-23
13:44
)
|
|
Atul
(
Results
-
Analysis
27-Apr-24
08:28
)
|
|
Atul
(
Results
-
Analysis
20-Jul-24
09:43
)
|
|
Atul’s arm gets EIR from US FDA for Ambernath facility
(
Hot Pursuit
-
12-Aug-24
08:48
)
|
|
Atul slides as Q3 PAT declines 32% YoY
(
Hot Pursuit
-
20-Jan-23
14:58
)
|
|
Atul to discuss results
(
Corporate News
-
31-Mar-22
09:44
)
|
|
Atul consolidated net profit rises 81.02% in the June 2019 quarter
(
Results
-
Announcements
26-Jul-19
17:40
)
|
|
Atul
(
Results
-
Analysis
29-Apr-23
07:58
)
|
|
Atul consolidated net profit declines 32.38% in the December 2022 quarter
(
Results
-
Announcements
20-Jan-23
15:35
)
|
|
|
|
Other Stories |
|
|
|
|
|